Skip to main content
Top
Published in: BMC Nephrology 1/2019

Open Access 01-12-2019 | Peritonitis | Case report

Rhodococcus induced false-positive galactomannan (GM), a biomarker of fungal presentation, in patients with peritoneal dialysis: case reports

Authors: Tamonwan Chamroensakchai, Wasin Manuprasert, Asada Leelahavanichkul, Kullaya Takkavatakarn, Nisa Thongbor, Bunpring Jaroenpattrawut, Talerngsak Kanjanabuch

Published in: BMC Nephrology | Issue 1/2019

Login to get access

Abstract

Background

Galactomannan index (GMI) at a level higher than 0.5 provides high sensitivity and specificity for the diagnosis of fungal peritonitis. Here, we report the false-positive of GMI in peritoneal dialysis (PD) effluent (PDE) due to Rhodococcus peritonitis in PD patients.

Case presentation

GMI in PDE of case #1 and case #2 were 1.53 and 0.76, respectively, while serum GMI of both cases was less than 0.5. In addition, GMI from the specimens obtained directly from the stationary phase of Rhodococcus colonies were 1.27 and 1.56, which were isolated from case #1 and #2, accordingly.

Conclusion

High GMI in PDE of PD patients is not specific just for fungal infections but may also be secondary to other infections, such as Rhodococcus spp., especially in endemic areas.
Literature
1.
go back to reference Wingard JR. Have novel serum markers supplanted tissue diagnosis for invasive fungal infections in acute leukemia and transplantation? Best Pract Res Clin Haematol. 2012;25(4):487–91.CrossRef Wingard JR. Have novel serum markers supplanted tissue diagnosis for invasive fungal infections in acute leukemia and transplantation? Best Pract Res Clin Haematol. 2012;25(4):487–91.CrossRef
2.
go back to reference Hachem RY, Kontoyiannis DP, Chemaly RF, Jiang Y, Reitzel R, Raad I. Utility of galactomannan enzyme immunoassay and (1,3) β-D-Glucan in diagnosis of invasive fungal infections: low sensitivity for aspergillus fumigatus infection in hematologic malignancy patients. J Clin Microbiol. 2009;47(1):129–33.CrossRef Hachem RY, Kontoyiannis DP, Chemaly RF, Jiang Y, Reitzel R, Raad I. Utility of galactomannan enzyme immunoassay and (1,3) β-D-Glucan in diagnosis of invasive fungal infections: low sensitivity for aspergillus fumigatus infection in hematologic malignancy patients. J Clin Microbiol. 2009;47(1):129–33.CrossRef
3.
go back to reference Worasilchai N, Leelahavanichkul A, Kanjanabuch T, Thongbor N, Lorvinitnun P, Sukhontasing K, et al. (1→3)-β-D-glucan and galactomannan testing for the diagnosis of fungal peritonitis in peritoneal dialysis patients, a pilot study. Med Mycol. 2015;53(4):338–46.CrossRef Worasilchai N, Leelahavanichkul A, Kanjanabuch T, Thongbor N, Lorvinitnun P, Sukhontasing K, et al. (1→3)-β-D-glucan and galactomannan testing for the diagnosis of fungal peritonitis in peritoneal dialysis patients, a pilot study. Med Mycol. 2015;53(4):338–46.CrossRef
4.
go back to reference Leelahavanichkul A, Pongpirul K, Thongbor N, Worasilchai N, Petphuak K, Thongsawang B, et al. (1→3)-β-D-Glucan and Galactomannan for a differentiation of chemical “black particles” and fungal particles inside peritoneal Dialysis tubing. Perit Dial Int. 2015;36:402–9.CrossRef Leelahavanichkul A, Pongpirul K, Thongbor N, Worasilchai N, Petphuak K, Thongsawang B, et al. (1→3)-β-D-Glucan and Galactomannan for a differentiation of chemical “black particles” and fungal particles inside peritoneal Dialysis tubing. Perit Dial Int. 2015;36:402–9.CrossRef
5.
go back to reference Navarro-Llorens JM, Patrauchan MA, Stewart GR, Davies JE, Eltis LD, Mohn WW. Phenylacetate catabolism in Rhodococcus sp. strain RHA1: a central pathway for degradation of aromatic compounds. J. Bacteriol. 2005;187(13):4497–504.CrossRef Navarro-Llorens JM, Patrauchan MA, Stewart GR, Davies JE, Eltis LD, Mohn WW. Phenylacetate catabolism in Rhodococcus sp. strain RHA1: a central pathway for degradation of aromatic compounds. J. Bacteriol. 2005;187(13):4497–504.CrossRef
6.
go back to reference Riesenberg A, Feßler AT, Erol E, Prenger-Berninghoff E, Stamm I, Böse R, et al. MICs of 32 antimicrobial agents for Rhodococcus equi isolates of animal origin. J Antimicrob Chemother. 2014;69(4):1045–9.CrossRef Riesenberg A, Feßler AT, Erol E, Prenger-Berninghoff E, Stamm I, Böse R, et al. MICs of 32 antimicrobial agents for Rhodococcus equi isolates of animal origin. J Antimicrob Chemother. 2014;69(4):1045–9.CrossRef
7.
go back to reference Daffe M, McNeil M, Brennan PJ. Major structural features of the cell wall arabinogalactans of Mycobacterium, Rhodococcus, and Nocardia spp. Carbohydr Res. 1993;249(2):383–98.CrossRef Daffe M, McNeil M, Brennan PJ. Major structural features of the cell wall arabinogalactans of Mycobacterium, Rhodococcus, and Nocardia spp. Carbohydr Res. 1993;249(2):383–98.CrossRef
8.
go back to reference Li PK, Szeto CC, Piraino B, de Arteaga J, Fan S, Figueiredo AE, et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment. Perit Dial Int. 2016;36(5):481–508.CrossRef Li PK, Szeto CC, Piraino B, de Arteaga J, Fan S, Figueiredo AE, et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment. Perit Dial Int. 2016;36(5):481–508.CrossRef
9.
go back to reference Stynen D, Sarfati J, Goris A, Prevost MC, Lesourd M, Kamphuis H, et al. Rat monoclonal antibodies against Aspergillus galactomannan. Infect Immun. 1992;60(6):2237–45.PubMedPubMedCentral Stynen D, Sarfati J, Goris A, Prevost MC, Lesourd M, Kamphuis H, et al. Rat monoclonal antibodies against Aspergillus galactomannan. Infect Immun. 1992;60(6):2237–45.PubMedPubMedCentral
10.
go back to reference Van Cutsem J, Meulemans L, Van Gerven F, Stynen D. Detection of circulating galactomannan by Pastorex Aspergillus in experimental invasive aspergillosis. Mycoses. 1990;33(2):61–9.CrossRef Van Cutsem J, Meulemans L, Van Gerven F, Stynen D. Detection of circulating galactomannan by Pastorex Aspergillus in experimental invasive aspergillosis. Mycoses. 1990;33(2):61–9.CrossRef
11.
go back to reference Giguere S, Lee EA, Guldbech KM, Berghaus LJ. In vitro synergy, pharmacodynamics, and postantibiotic effect of 11 antimicrobial agents against Rhodococcus equi. Vet Microbiol. 2012;160(1–2):207–13.CrossRef Giguere S, Lee EA, Guldbech KM, Berghaus LJ. In vitro synergy, pharmacodynamics, and postantibiotic effect of 11 antimicrobial agents against Rhodococcus equi. Vet Microbiol. 2012;160(1–2):207–13.CrossRef
12.
go back to reference Kedlaya I, Ing MB, Wong SS. Rhodococcus equi infections in immunocompetent hosts: case report and review. Clin Infect Dis. 2001;32(3):E39–46.CrossRef Kedlaya I, Ing MB, Wong SS. Rhodococcus equi infections in immunocompetent hosts: case report and review. Clin Infect Dis. 2001;32(3):E39–46.CrossRef
13.
go back to reference Tang S, Lo CY, Lo WK, Ho M, Cheng IK. Rhodococcus peritonitis in continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant. 1996;11(1):201–2.CrossRef Tang S, Lo CY, Lo WK, Ho M, Cheng IK. Rhodococcus peritonitis in continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant. 1996;11(1):201–2.CrossRef
Metadata
Title
Rhodococcus induced false-positive galactomannan (GM), a biomarker of fungal presentation, in patients with peritoneal dialysis: case reports
Authors
Tamonwan Chamroensakchai
Wasin Manuprasert
Asada Leelahavanichkul
Kullaya Takkavatakarn
Nisa Thongbor
Bunpring Jaroenpattrawut
Talerngsak Kanjanabuch
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2019
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-019-1642-1

Other articles of this Issue 1/2019

BMC Nephrology 1/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.